Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: Healthy
Interventions: Cefprozil for oral suspension 250 mg/5 mL, CEFZIL® for Oral Suspension 250 mg/5mL; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Healthy
Interventions: Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: ALXN1840, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Body Weight Changes
Interventions: MicroDiet, Healthy Diet; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Obesity
Interventions: Intervention Group, Control Group; Behavioral
Lead sponsor: BETH COMERFORD; Other
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Interventions: Time Limited Eating, Components Common to All Study Arms., Control, Continuous Glucose Monitor; Behavioral · Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 21 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Transplant Surgery
Interventions: TetraGraph on dominant hand, TetraGraph on non-dominant hand; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypoglycemia
Interventions: Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor; Other · Genetic · Diagnostic Test
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Impaired Glucose Tolerance
Interventions: Resveratrol, resveratrol /HMB, Placebo treatment; Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Healthy
Interventions: Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Drug Drug Interaction
Interventions: Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet; Drug
Lead sponsor: Blade Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma and Brain Metastases
Interventions: Dabrafenib 150 mg, Trametinib 2.0 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Healthy
Interventions: Fosinopril 40mg Tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Lactose Intolerance
Interventions: RP-G28; Drug
Lead sponsor: Ritter Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Gestational Diabetes
Interventions: Blood glucose testing; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Danville, Pennsylvania • Providence, Rhode Island • Houston, Texas

Conditions: Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions: Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon, [1-13C] glucose, [2-13C] glucose; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Cancer
Interventions: exercise (walking), plasma samples, blood draw; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Boulder, Colorado • Middletown, New Jersey + 7 more

Conditions: Breast Cancer
Interventions: GDC-0810, LHRH Agonist, Palbociclib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: HCV Infection
Interventions: ABT-450, ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Cancer
Interventions: FACBC PET-CT Imaging; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infection Due to Resistant Organism
Interventions: Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling, Fasting; Biological · Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more

Search by objective public record fields.

Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet

Fruit and Vegetable Prescription Program

Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)

Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation

Mechanisms of Hypoglycemia in Patients Without Diabetes

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Frequency of Blood Glucose Monitoring in Patients With Gestational Diabetes

Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)

Researching the Effect of Aerobic Exercise on Cancer

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

FMT for MDRO Colonization After Infection in Renal Transplant Recipients

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia